Literature DB >> 25986997

Monogenic glucokinase diabetes and pregnancy: a case study.

Iva Haladová1, Daniela Čechurová, Silvie Lacigová, Zdeněk Rušavý.   

Abstract

It is estimated that up to 3 % of patients with gestational diabetes have glucokinase diabetes, termed also maturity-onset diabetes of the young type 2. The disorder has autosomal dominant inheritance. There is a 50 % risk of transmission of the gene to next generation. Two scenarios with different approach to the treatment may occur in pregnancy with glucokinase diabetes: either the fetus inherits the glucokinase mutation and the treatment of maternal hyperglycemia by insulin could increase the risk of fetal growth restriction, or the fetus is without glucokinase gene mutation and untreated hyperglycemia of the mother increases the risk of macrosomia and perinatal morbidity and insulin therapy is necessary. This article describes the outcome of two pregnancies in a patient with monogenic diabetes with glucokinase deficiency. A specific approach to the treatment is discussed.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25986997     DOI: 10.1007/s00508-015-0795-6

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  8 in total

1.  Preconception care and the risk of congenital anomalies in the offspring of women with diabetes mellitus: a meta-analysis.

Authors:  J G Ray; T E O'Brien; W S Chan
Journal:  QJM       Date:  2001-08

2.  A high prevalence of glucokinase mutations in gestational diabetic subjects selected by clinical criteria.

Authors:  S Ellard; F Beards; L I Allen; M Shepherd; E Ballantyne; R Harvey; A T Hattersley
Journal:  Diabetologia       Date:  2000-02       Impact factor: 10.122

3.  Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma.

Authors:  Rossa W K Chiu; K C Allen Chan; Yuan Gao; Virginia Y M Lau; Wenli Zheng; Tak Y Leung; Chris H F Foo; Bin Xie; Nancy B Y Tsui; Fiona M F Lun; Benny C Y Zee; Tze K Lau; Charles R Cantor; Y M Dennis Lo
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-10       Impact factor: 11.205

4.  Pregnancy outcome in patients with raised blood glucose due to a heterozygous glucokinase gene mutation.

Authors:  G Spyer; K M Macleod; M Shepherd; S Ellard; A T Hattersley
Journal:  Diabet Med       Date:  2009-01       Impact factor: 4.359

5.  Mutations in the glucokinase gene of the fetus result in reduced birth weight.

Authors:  A T Hattersley; F Beards; E Ballantyne; M Appleton; R Harvey; S Ellard
Journal:  Nat Genet       Date:  1998-07       Impact factor: 38.330

6.  The genetic abnormality in the beta cell determines the response to an oral glucose load.

Authors:  A Stride; M Vaxillaire; T Tuomi; F Barbetti; P R Njølstad; T Hansen; A Costa; I Conget; O Pedersen; O Søvik; R Lorini; L Groop; P Froguel; A T Hattersley
Journal:  Diabetologia       Date:  2002-03       Impact factor: 10.122

7.  Antenatal diagnosis of fetal genotype determines if maternal hyperglycemia due to a glucokinase mutation requires treatment.

Authors:  Ali J Chakera; Victoria L Carleton; Sian Ellard; Jencia Wong; Dennis K Yue; Jason Pinner; Andrew T Hattersley; Glynis P Ross
Journal:  Diabetes Care       Date:  2012-07-06       Impact factor: 19.112

8.  Comment on: Chakera et al. Antenatal diagnosis of fetal genotype determines if maternal hyperglycemia due to a glucokinase mutation requires treatment. Diabetes Care 2012;35:1832-1834.

Authors:  Edoardo Tartaglia; Dario Iafusco; Piero Giuliano; Brunella Giugliano; Teresa Sena; Angelo Perrotta; Pasquale Mastrantonio
Journal:  Diabetes Care       Date:  2013-01       Impact factor: 19.112

  8 in total
  1 in total

Review 1.  The Challenges of Treating Glucokinase MODY during Pregnancy: A Review of Maternal and Fetal Outcomes.

Authors:  Alena Kirzhner; Oren Barak; Edi Vaisbuch; Taiba Zornitzki; Tal Schiller
Journal:  Int J Environ Res Public Health       Date:  2022-05-14       Impact factor: 4.614

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.